AnaptysBio, Inc. (ANAB)
51.96
+0.33
(+0.64%)
USD |
NASDAQ |
Jun 10, 16:00
51.96
0.00 (0.00%)
After-Hours: 20:00
AnaptysBio Total Return Price : 51.96 for June 10, 2026
Total Return Price Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Return Price Data
| Date | Value |
|---|---|
| June 09, 2026 | 51.63 |
| June 08, 2026 | 51.36 |
| June 05, 2026 | 50.37 |
| June 04, 2026 | 51.67 |
| June 03, 2026 | 51.24 |
| June 02, 2026 | 51.26 |
| June 01, 2026 | 53.14 |
| May 29, 2026 | 55.67 |
| May 28, 2026 | 57.02 |
| May 27, 2026 | 57.69 |
| May 26, 2026 | 57.77 |
| May 22, 2026 | 59.71 |
| May 21, 2026 | 60.41 |
| May 20, 2026 | 60.08 |
| May 19, 2026 | 59.77 |
| May 18, 2026 | 58.74 |
| May 15, 2026 | 63.15 |
| May 14, 2026 | 62.19 |
| May 13, 2026 | 62.68 |
| May 12, 2026 | 65.58 |
| May 11, 2026 | 67.92 |
| May 08, 2026 | 69.33 |
| May 07, 2026 | 66.96 |
| May 06, 2026 | 67.36 |
| May 05, 2026 | 69.28 |
| Date | Value |
|---|---|
| May 04, 2026 | 69.78 |
| May 01, 2026 | 66.76 |
| April 30, 2026 | 65.73 |
| April 29, 2026 | 62.34 |
| April 28, 2026 | 66.11 |
| April 27, 2026 | 66.59 |
| April 24, 2026 | 58.88 |
| April 23, 2026 | 51.27 |
| April 22, 2026 | 53.55 |
| April 21, 2026 | 51.82 |
| April 20, 2026 | 50.95 |
| April 17, 2026 | 45.00 |
| April 16, 2026 | 44.59 |
| April 15, 2026 | 45.25 |
| April 14, 2026 | 46.81 |
| April 13, 2026 | 45.81 |
| April 10, 2026 | 46.73 |
| April 09, 2026 | 45.69 |
| April 08, 2026 | 43.69 |
| April 07, 2026 | 41.41 |
| April 06, 2026 | 41.61 |
| April 02, 2026 | 38.45 |
| April 01, 2026 | 37.81 |
| March 31, 2026 | 36.97 |
| March 30, 2026 | 36.92 |
Total Return Price Definition
The total return price allows investors to view the performance of a security inclusive of both price appreciation and dividends/distributions.
Total Return Price Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Return Price Benchmarks
| Agenus, Inc. | 3.065 |
| Vanda Pharmaceuticals, Inc. | 6.035 |
| Precision BioSciences, Inc. | 6.475 |
| Amgen, Inc. | 337.70 |
| BioCryst Pharmaceuticals, Inc. | 8.19 |